TOP TEN perturbations for 38403_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38403_at
Selected probe(set): 203041_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38403_at (203041_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):-3.899787Number of Samples:2 / 5
Experimental | kidney transplantation study 15 (8 week) |
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
Control | normal monocyte (CD14+) sample |
CD14+ monocyte samples derived from healthy control subjects. |
conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):3.140727Number of Samples:2 / 2
Experimental | conditioned medium study 1 (HS27a) |
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h. | |
Control | untreated monocyte (CD14+) sample |
Untreated CD14+ monocytes from two different donors. |
CML study 1 / B-CLL study 5
Relative Expression (log2-ratio):3.1287003Number of Samples:75 / 441
Experimental | CML study 1 |
Bone marrow samples of patients with chronic myeloid leukemia (CML). | |
Control | B-CLL study 5 |
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL). |
precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample
Relative Expression (log2-ratio):-3.0081968Number of Samples:36 / 74
Experimental | precursor-B-ALL study 1 (t(1;19)(q23,q13)) |
Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1). | |
Control | normal bone marrow sample |
Non-leukemic and healthy bone marrow sample. |
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):-2.8358688Number of Samples:2 / 2
Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):2.8105183Number of Samples:2 / 2
Experimental | conditioned medium study 1 (HS5) |
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h. | |
Control | untreated monocyte (CD14+) sample |
Untreated CD14+ monocytes from two different donors. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-2.8005095Number of Samples:3 / 3
Experimental | oncolytic herpes simplex virus study 2 |
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary) / expO ovary cancer study 1 (carcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.6653013Number of Samples:3 / 2
Experimental | expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary) |
Primary tumor tissue samples obtained from the ovary of patients with malignant mixed Mullerian tumor. | |
Control | expO ovary cancer study 1 (carcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the ovary of patients with carcinoma (NOS). |
expO ovary cancer study 1 (mixed epithelial tumor; primary) / expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary)
Relative Expression (log2-ratio):2.627038Number of Samples:3 / 3
Experimental | expO ovary cancer study 1 (mixed epithelial tumor; primary) |
Primary tumor tissue samples obtained from the ovary of patients with mixed epithelial tumor. | |
Control | expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary) |
Primary tumor tissue samples obtained from the ovary of patients with malignant mixed Mullerian tumor. |
expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary) / expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.5468655Number of Samples:3 / 12
Experimental | expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary) |
Primary tumor tissue samples obtained from the ovary of patients with malignant mixed Mullerian tumor. | |
Control | expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the ovary of patients with clear cell adenocarcinoma (NOS). |